FATE THERAPEUTICS INC (FATE) Form SCHEDULE 13D/A — Nov 9, 2026

$FATEForm SCHEDULE 13D/AFiled Nov 9, 2026, 7:08 PM ET0000905148-26-004718Original filing

Redmile Group, Jeremy C. Green, and affiliated funds filed Amendment No. 11 to their Schedule 13D on Fate Therapeutics, adding Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership crossed 5% solely due to an increase in Fate's shares outstanding disclosed in the Q3 2026 Form 10-Q.

Key figures

Shares Outstanding: 121568755
Redco ii shares: 10144307
Percent of class: 14.99%
Redco ii percent: 8.12%
Redmile offshore ii shares: 6426298
Ownership blocker threshold: 14.99%
Redmile offshore ii percent: 5.03%
Prefunded warrant exercise price: $0.001
Class a preferred conversion ratio: one-for-five
Aggregate shares beneficially owned: 19164572

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.